SWOG clinical trial number
E1A95
A Phase III Study of PSC-833 in Combination With Vincristine Doxorubicin and Dexamethasone (PSC-833/VAD) Versus VAD Alone in Patients With Relapsing or Refractory Multiple Myeloma
Closed
Phase
Abbreviated Title
A Phase III Study of PSC-833 in Combination With Vincristine Doxorubicin and Dexamethasone (PSC-833/VAD) Versus VAD Alone in Patients With Relapsing or Refractory Multiple Myeloma
Activated
09/15/1997
Closed
06/15/1999
Publication Information Expand/Collapse
2006
Phase III study of PSC-833 (valspodarz) in combination with vincristin, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group [PMID16419071]